BackLipella Pharmaceuticals Overview

Lipella Pharmaceuticals Total Assets

Lipella Pharmaceuticals's total assets is $2.3B.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$2.35B
↑ 8.78% YoYΔ $189.71M vs prior year quarter

Peer average

Loading

Lipella Pharmaceuticals Total Assets History

Loading

Lipella Pharmaceuticals vs. peers: Total Assets Comparison

Loading

Lipella Pharmaceuticals Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Lipella Pharmaceuticals (LIPO) FAQ

As of the most recent data (September 2025), LIPO shows a total assets of $2.3B. That compares with $2.2B in the prior-year period — up 8.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LIPO's total assets is now $2.3B (was $2.2B) — a 8.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Lipella Pharmaceuticals is outperforming or lagging.

Tracking LIPO's total assets over time shows whether Lipella Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $2.3B That compares with $2.2B in the prior-year period — up 8.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Lipella Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $2.3B) with ownership activity and broader fundamentals.